Creditos
Bus.Valor
Bus.User
Foro de PHARMA MAR
No puedes escribir, haz LOGIN en PCBOLSA
CONECTARSE
CONECTARSE
Todos
PHM
Mensaje de: amperiano2015 Hora: 03/07/2026 16:30:35
Y todos los que no salimos en 105 animados por los coheteros...
Y todos los que no salimos en 105 animados por los coheteros...
yo me incluyo que no vendí en 105 pero y hasta que no sales ni ganas ni pierdes, pero hay muchos que se vendieron en pérdidas por la bajada y los comentarios y eso me jode
1
Mensaje de: ECS1 Hora: 03/07/2026 16:40:40
O sea que pharmamar está como preocupada por el prox informe JCA pq parece ser que no se aplicó correctamente el tema de la metodología para medicamentos huérfanos .
De donde sacan esto ?
PHM no dijo nada en la junta sobre esto
Yo le iba a preguntar pero ..fue no hubo más tiempo
De donde sacan esto ?
PHM no dijo nada en la junta sobre esto
Yo le iba a preguntar pero ..fue no hubo más tiempo
19
Si si James... pero aqui estamos. Hablo por mi, supongo que algún dia aprenderé a no ser tan avaricioso...
Vamoooos
Vamoooos
0
Apuesto por un cierre debajo de 80
Otra cosa sería una sorpresa, siguen mandando los cortos
Otra cosa sería una sorpresa, siguen mandando los cortos
0
Mensaje de: ECS1 Hora: 03/07/2026 16:40:40
El título al traducirlo os da error , coge un significado que no es
19
Mensaje de: ECS1 Hora: 03/07/2026 16:40:40
Key Takeaways
PharmaMar has raised concerns about the joint clinical assessment process under the EU Health Technology Assessment Regulation.
It says that orphan drugs like Zepzelca cannot be assessed in the same way as non-orphan products.
PharmaMar also commented that the JCA was demanding and little of its feedback to the points raised through the process was incorporated into the final assessment.
PharmaMar has raised concerns about the joint clinical assessment process under the EU Health Technology Assessment Regulation.
It says that orphan drugs like Zepzelca cannot be assessed in the same way as non-orphan products.
PharmaMar also commented that the JCA was demanding and little of its feedback to the points raised through the process was incorporated into the final assessment.
19
Mensaje de: JM Chao Hora: 03/07/2026 16:54:58
Apuesto por un cierre debajo de 80 Otra cosa sería una sorpresa, siguen mandando los cortos
Apuesto por un cierre debajo de 80 Otra cosa sería una sorpresa, siguen mandando los cortos
Pues llevan perdidos 14€, casi 20%
Mandar, deben mandar en su casa a la hora de comer...
Mandar, deben mandar en su casa a la hora de comer...
1
Mensaje de: ECS1 Hora: 03/07/2026 16:40:40
La Francesca tiene que tener alguna info del tribunal o algo
No hay nada público referente a ninguna queja de PHM sobre el tema
No hay nada público referente a ninguna queja de PHM sobre el tema
19
Mensaje de: ECS1 Hora: 03/07/2026 16:40:40
Joint Clinical Assessments
Joint clinical assessments (JCAs) are likely to be game changing for the way pricing and reimbursement is decided by EU member states and for the way that drug companies prepare for market access. They are similar to relative efficacy assessments carried out by member states health technology assessment (HTA) bodies and must be given “due consideration” by national HTA bodies in their assessments .
JCAs came into effect under the HTA Regulation in January 2025 for advanced medicinal therapy products (ATMPs), many of which are for rare diseases, and oncology products. JCAs will be applicable to all other types of medicines with EU orphan drug status from January 2028 and to all other drugs that are centrally authorized in the EU from 2030.
Joint clinical assessments (JCAs) are likely to be game changing for the way pricing and reimbursement is decided by EU member states and for the way that drug companies prepare for market access. They are similar to relative efficacy assessments carried out by member states health technology assessment (HTA) bodies and must be given “due consideration” by national HTA bodies in their assessments .
JCAs came into effect under the HTA Regulation in January 2025 for advanced medicinal therapy products (ATMPs), many of which are for rare diseases, and oncology products. JCAs will be applicable to all other types of medicines with EU orphan drug status from January 2028 and to all other drugs that are centrally authorized in the EU from 2030.
19
Mensaje de: ECS1 Hora: 03/07/2026 16:40:40
The JCA reports are carried out by assessors and co-assessors on behalf of the EU’s Coordination Group on Health Technology Assessment, which is made up of member states’ representatives, mainly from HTA authorities.
The JCA assessment process runs in parallel with the European Medicines Agency’s process for reviewing marketing authorization applications (MAAs). Companies should submit relevant information for the JCA to the European Commission’s HTA Secretariat at the same time that they submit their MAAs to the EMA.
The JCA assessment process runs in parallel with the European Medicines Agency’s process for reviewing marketing authorization applications (MAAs). Companies should submit relevant information for the JCA to the European Commission’s HTA Secretariat at the same time that they submit their MAAs to the EMA.
19
Noticias
MERCADO ESPAÑOL
Indice
Ultimo
DIF
HORA
IBEX 35
OTROS MERCADOS
información PHARMA MAR
CNMV Links PHARMA MAR
Datos Generales
Acciones:
18.000.000
Capitalización:
1.478.700.000 €
Máximo Hoy:
83,300 (2,02 )
Mínimo Hoy:
81,900 (0,31 )
Ayer:
81,650
Open:
82,700
GAP:
1,29 %
ISIN:
ES0169501022
Rent. 1 Semana:
3,92%
Rent. 1 Mes:
-1,97%
Rent. Anual:
9,68%
Rent. 1 Año:
0,49%
Rent. 3 Año:
178,06%
UILTIMAS RECOMENDACIONES
BROKER
FECHA
Pre.Obj
Pre.Ant
Bestinver Secu
24/02/2026
93,00
90,00
JB Capital Mar
13/02/2025
118,00
95,00
JB Capital Mar
16/10/2024
102,00
57,00
RX Securities
16/10/2024
80,00
65,00
NEEDHAM
18/09/2024
72,00
70,00
Bestinver Secu
24/02/2026
93,00
90,00
JB Capital Mar
13/02/2025
118,00
95,00
JB Capital Mar
16/10/2024
102,00
57,00
RX Securities
16/10/2024
80,00
65,00
NEEDHAM
18/09/2024
72,00
70,00
